• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

埃博拉病毒的物种和变体特异性的致病性和毒力。

Pathogenicity and Virulence of Ebolaviruses with Species- and Variant-specificity.

机构信息

Department of Molecular Medicine, Mayo Clinic, Rochester, USA.

出版信息

Virulence. 2021 Dec;12(1):885-901. doi: 10.1080/21505594.2021.1898169.

DOI:10.1080/21505594.2021.1898169
PMID:33734027
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7993122/
Abstract

Ebola virus (EBOV), belonging to the species in the genus , causes a severe febrile illness in humans with case fatality rates (CFRs) up to 90%. While there have been six virus species classified, which each have a single type virus in the genus , CFRs of ebolavirus infections vary among viruses belonging to each distinct species. In this review, we aim to define the ebolavirus species-specific virulence on the basis of currently available laboratory and experimental findings. In addition, this review will also cover the variant-specific virulence of EBOV by referring to the unique biological and pathogenic characteristics of EBOV variant Makona, a new EBOV variant isolated from the 2013-2016 EBOV disease outbreak in West Africa. A better definition of species-specific and variant-specific virulence of ebolaviruses will facilitate our comprehensive knowledge on genus biology, leading to the development of therapeutics against well-focused pathogenic mechanisms of each Ebola disease.

摘要

埃博拉病毒(EBOV)属于丝状病毒科中的 属,可引起人类严重的发热疾病,病死率(CFR)高达 90%。虽然已经分类了六种病毒物种,每种病毒都属于单一的属病毒,但属于每个不同物种的埃博拉病毒的 CFR 有所不同。在这篇综述中,我们旨在根据目前可用的实验室和实验结果来定义埃博拉病毒的种特异性毒力。此外,本文还将通过参考 2013-2016 年西非埃博拉病毒病暴发期间分离出的新型埃博拉病毒变异株 Makona 的独特生物学和发病机制特性,涵盖 EBOV 的变异特异性毒力。更好地定义埃博拉病毒的种特异性和变异特异性毒力将有助于我们全面了解属生物学,从而开发针对每种埃博拉病的有针对性的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8daa/7993122/fefa219fa09b/KVIR_A_1898169_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8daa/7993122/8e32be0f2f5f/KVIR_A_1898169_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8daa/7993122/daf9dbd1d9a9/KVIR_A_1898169_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8daa/7993122/fefa219fa09b/KVIR_A_1898169_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8daa/7993122/8e32be0f2f5f/KVIR_A_1898169_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8daa/7993122/daf9dbd1d9a9/KVIR_A_1898169_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8daa/7993122/fefa219fa09b/KVIR_A_1898169_F0003_OC.jpg

相似文献

1
Pathogenicity and Virulence of Ebolaviruses with Species- and Variant-specificity.埃博拉病毒的物种和变体特异性的致病性和毒力。
Virulence. 2021 Dec;12(1):885-901. doi: 10.1080/21505594.2021.1898169.
2
Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston).关于雷斯顿埃博拉病毒低毒力的现有知识(法语:Connaissances actuelles sur la moindre virulence du virus Ebola Reston)
Comp Immunol Microbiol Infect Dis. 2007 Sep;30(5-6):391-8. doi: 10.1016/j.cimid.2007.05.005. Epub 2007 Jul 3.
3
Serological evidence of exposure to ebolaviruses in domestic pigs from Guinea.来自几内亚的家猪中埃博拉病毒感染的血清学证据。
Transbound Emerg Dis. 2020 Mar;67(2):724-732. doi: 10.1111/tbed.13391. Epub 2019 Nov 2.
4
Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.α/β干扰素受体缺陷小鼠作为埃博拉病毒病的模型
J Infect Dis. 2015 Oct 1;212 Suppl 2:S282-94. doi: 10.1093/infdis/jiv215. Epub 2015 May 4.
5
Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.三价副流感病毒载体埃博拉病毒疫苗诱导的抗体介导的保护机制。
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01845-18. Print 2019 Feb 15.
6
Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.基于痘病毒的埃博拉病毒表达 GP 和 VP40 蛋白疫苗候选物的免疫原性和疗效的差异。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.00363-18. Print 2018 Jun 1.
7
General introduction into the Ebola virus biology and disease.埃博拉病毒生物学与疾病概述
Folia Med Cracov. 2014;54(3):57-65.
8
The serology of Ebolavirus - a wider geographical range, a wider genus of viruses or a wider range of virulence?埃博拉病毒血清学——更广泛的地理范围、更广泛的病毒属还是更广泛的毒力范围?
J Gen Virol. 2016 Dec;97(12):3120-3130. doi: 10.1099/jgv.0.000638. Epub 2016 Oct 21.
9
Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling.存活与适应性免疫的早期激活和髓系来源的抑制性细胞信号的减少相关。
mBio. 2021 Aug 31;12(4):e0151721. doi: 10.1128/mBio.01517-21. Epub 2021 Aug 10.
10
Spontaneous Mutation at Amino Acid 544 of the Ebola Virus Glycoprotein Potentiates Virus Entry and Selection in Tissue Culture.埃博拉病毒糖蛋白第544位氨基酸的自发突变增强了病毒在组织培养中的进入和选择。
J Virol. 2017 Jul 12;91(15). doi: 10.1128/JVI.00392-17. Print 2017 Aug 1.

引用本文的文献

1
The Ebola virus - going beyond the bleeding edge.埃博拉病毒——超越前沿。
J Med Microbiol. 2025 Jul;74(7). doi: 10.1099/jmm.0.001998.
2
Rapid laboratory confirmation of the 2025 Sudan Virus Disease (Svd) index case in Uganda.乌干达2025年苏丹病毒病(Svd)首例病例的快速实验室确诊。
BMC Infect Dis. 2025 Jul 2;25(1):888. doi: 10.1186/s12879-025-11271-0.
3
Non-Ebola Filoviruses: Potential Threats to Global Health Security.非埃博拉丝状病毒:对全球卫生安全的潜在威胁。

本文引用的文献

1
A Glycoprotein Mutation That Emerged during the 2013-2016 Ebola Virus Epidemic Alters Proteolysis and Accelerates Membrane Fusion.一种在 2013-2016 年埃博拉病毒流行期间出现的糖蛋白突变改变了蛋白水解作用并加速了膜融合。
mBio. 2021 Feb 16;12(1):e03616-20. doi: 10.1128/mBio.03616-20.
2
Ebola.埃博拉
N Engl J Med. 2020 May 7;382(19):1832-1842. doi: 10.1056/NEJMra1901594.
3
Ebola-Specific CD8+ and CD4+ T-Cell Responses in Sierra Leonean Ebola Virus Survivors With or Without Post-Ebola Sequelae.塞拉利昂埃博拉幸存者有无埃博拉后遗症患者体内的埃博拉特异性 CD8+和 CD4+ T 细胞应答。
Viruses. 2024 Jul 23;16(8):1179. doi: 10.3390/v16081179.
4
High Seroreactivities to Orthoebolaviruses in Rural Cameroon: A Case-Control Study on Nonhuman Primate Bites and a Cross-sectional Survey in Rural Populations.高血清对 Orthoebolaviruses 在喀麦隆农村地区的反应:关于非人类灵长类动物咬伤的病例对照研究和农村人群的横断面调查。
J Infect Dis. 2024 Nov 15;230(5):e1067-e1076. doi: 10.1093/infdis/jiae399.
5
Development of a Crystallographic Screening to Identify Sudan Virus VP40 Ligands.用于鉴定苏丹病毒VP40配体的晶体学筛选方法的开发。
ACS Omega. 2024 Jul 18;9(30):33193-33203. doi: 10.1021/acsomega.4c04829. eCollection 2024 Jul 30.
6
Prevalence of somatic symptoms among Ebola Virus Disease (EVD) survivors in Africa: a systematic review and meta-analysis.非洲埃博拉病毒病(EVD)幸存者躯体症状的流行情况:系统评价和荟萃分析。
BMC Public Health. 2024 Jun 5;24(1):1511. doi: 10.1186/s12889-024-19013-8.
7
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.异源cAd3-埃博拉疫苗和MVA-埃博拉Z疫苗在美国和乌干达的1/1b期试验中安全且具有免疫原性。
NPJ Vaccines. 2024 Mar 29;9(1):67. doi: 10.1038/s41541-024-00833-z.
8
Geographic Disparities in Domestic Pig Population Exposure to Ebola Viruses, Guinea, 2017-2019.2017-2019 年,几内亚国内猪群接触埃博拉病毒的地理差异。
Emerg Infect Dis. 2024 Apr;30(4):681-690. doi: 10.3201/eid3004.231034.
9
Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches.探索埃博拉病毒感染治疗的复杂领域:新兴药理学方法综述
Infect Dis Ther. 2024 Jan;13(1):21-55. doi: 10.1007/s40121-023-00913-y. Epub 2024 Jan 19.
10
Domestic pigs are susceptible to experimental infection with non-human primate-derived Reston virus without the need for adaptation.家猪无需适应即可感染非人类灵长类动物源性雷斯顿病毒。
Sci Rep. 2024 Jan 6;14(1):715. doi: 10.1038/s41598-024-51280-8.
J Infect Dis. 2020 Oct 1;222(9):1488-1497. doi: 10.1093/infdis/jiaa268.
4
Early Transcriptional Changes within Liver, Adrenal Gland, and Lymphoid Tissues Significantly Contribute to Ebola Virus Pathogenesis in Cynomolgus Macaques.早期在肝脏、肾上腺和淋巴组织中的转录变化显著促进了食蟹猴体内埃博拉病毒的发病机制。
J Virol. 2020 May 18;94(11). doi: 10.1128/JVI.00250-20.
5
The Utility of Human Immune System Mice for High-Containment Viral Hemorrhagic Fever Research.人类免疫系统小鼠在高防护病毒性出血热研究中的应用
Vaccines (Basel). 2020 Feb 22;8(1):98. doi: 10.3390/vaccines8010098.
6
Ebola virus disease.埃博拉病毒病。
Nat Rev Dis Primers. 2020 Feb 20;6(1):13. doi: 10.1038/s41572-020-0147-3.
7
Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics.用于埃博拉病毒病(EVD)治疗药物研发的恒河猴 EVD 特征描述。
Viruses. 2020 Jan 13;12(1):92. doi: 10.3390/v12010092.
8
Generation and Characterization of a Mouse-Adapted Makona Variant of Ebola Virus.生成和鉴定埃博拉病毒马科纳变异株的小鼠适应株。
Viruses. 2019 Oct 26;11(11):987. doi: 10.3390/v11110987.
9
Investigating the Cellular Transcriptomic Response Induced by the Makona Variant of Ebola Virus in Differentiated THP-1 Cells.研究马科纳变异型埃博拉病毒在分化的 THP-1 细胞中诱导的细胞转录组反应。
Viruses. 2019 Nov 4;11(11):1023. doi: 10.3390/v11111023.
10
The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development.埃博拉病毒可溶性糖蛋白在复制、发病机制和对策开发中的作用。
Viruses. 2019 Oct 31;11(11):999. doi: 10.3390/v11110999.